H. Lundbeck A/S- (OTCMKTS:HLUYY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday. The firm presently has a $54.00 price objective on the stock. Zacks Investment Research‘s price target indicates a potential upside of 13.30% from the company’s previous close.
According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “
Shares of H. Lundbeck A/S- (OTCMKTS HLUYY) traded down $0.20 during midday trading on Friday, reaching $47.66. 7,192 shares of the company were exchanged, compared to its average volume of 3,263. The firm has a market cap of $9,530.00, a PE ratio of 22.38, a price-to-earnings-growth ratio of 1.00 and a beta of 0.19. H. Lundbeck A/S- has a 12-month low of $38.21 and a 12-month high of $66.67. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.93 and a current ratio of 1.21.
ILLEGAL ACTIVITY NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.com-unik.info/2017/12/15/h-lundbeck-as-hluyy-raised-to-buy-at-zacks-investment-research.html.
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.
What are top analysts saying about H. Lundbeck A/S-? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for H. Lundbeck A/S- and related companies.